Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

From 1986 to 1991, 602 patients with melioidosis were seen in Sappasitprasong Hospital, Ubon Ratchatani, Thailand. The in-hospital mortality was 42%. Of 118 adult patients followed long-term, 27 (23%) had culture-proven relapses of melioidosis (3 relapsed twice), a relapse rate of 15% (95% confidence interval [CI], 11-22) per year. The median time from discharge to relapse was 21 weeks (range, 1-290). In 44% of patients, relapses included septicemia, and 27% died. Patients with severe disease (multiple foci of infection or septicemia) relapsed 4.7 times (95% CI, 1.6-14.1) more frequently than patients with localized melioidosis. Underlying disease was not a risk factor, but initial parenteral treatment with ceftazidime reduced the risk of relapse 2-fold (95% CI, 1.1-3.4). Relapses were 3.3 (95% CI, 1.4-9.0) times more frequent following short-course (< or = 8 weeks) oral coamoxiclav than after the oral combination regimen of chloramphenicol, doxycycline, and cotrimoxazole. Longer oral treatment with either reduced relapse 1.6-fold (95% CI, 1.2-1.9). The optimum choice and duration of antibiotic treatment to prevent relapse in melioidosis remain to be determined.

Type

Journal article

Journal

The Journal of infectious diseases

Publication Date

11/1993

Volume

168

Pages

1181 - 1185

Addresses

Department of Medicine, Sappasitprasong Hospital, Ubon Ratchatani, Thailand.

Keywords

Humans, Melioidosis, Recurrence, Chloramphenicol, Ceftazidime, Clavulanic Acids, Amoxicillin-Potassium Clavulanate Combination, Amoxicillin, Trimethoprim-Sulfamethoxazole Combination, Doxycycline, Drug Combinations, Anti-Bacterial Agents, Risk Factors, Prospective Studies, Adolescent, Adult, Middle Aged, Thailand, Female, Male